ReviewThe Biochemical journal2026
Non-canonical and constitutive activation of small GTPases: more than an exception to the rule?
Review in The Biochemical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The superfamily of small GTPases comprises over 150 members, clustered in different families (e.g., Ras, Rab, Rho), that together are essential for a wide range of cellular functions. Most GTPases behave as molecular on/off switches, with regulatory proteins controlling their cycling between the GDP-bound, inactive form and the GTP-bound, active form. However, there is a substantial number of small GTPases that do not adhere to this canonical mode of regulation. This can result from key sequence differences that maintain these GTPases mostly in the GTP-bound form. Alternatively, specific post-translational modifications, including ubiquitination or alternative lipidation, can activate these GTPases, for example, due to interference with their intrinsic GTP hydrolysis capacity. Such 'atypical' GTPases are often constitutively active and are furthermore characterized by fast turnover. Consequently, their output is much more a function of their expression levels, with proteasomal or lysosomal degradation limiting their signaling capacity. This review discusses recent insights into non-canonical activation of small GTPases. We also discuss modifications, in particular palmitoylation, which allows otherwise canonical GTPases to become (constitutively) active, escaping their usual regulatory mechanisms. Finally, we discuss the potential biological importance of non-canonical GTPase regulation. We focus on the difference in kinetics and signal duration between canonical cycling versus non-canonical activation, and discuss differences related to fast, external stimulation (e.g., by hormones and growth factors) versus slow, intrinsic signaling, linked to altered metabolism, autophagy, or disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.